Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

Key Points

• Oric Pharmaceuticals is set to announce its Q2 2025 earnings on August 11, with analysts predicting a loss of $0.46 per share for the quarter.
• Recent analyst ratings show an average rating of "Buy" for Oric Pharmaceuticals, with a price target averaging $18.57, reflecting positive sentiment towards the company's growth prospects.
• Insider activity includes Director Angie You purchasing 26,597 shares at $9.39 per share, while CFO Dominic Piscitelli sold 32,466 shares at $10.50, indicating mixed signals on insider confidence.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.46) per share for the quarter.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. On average, analysts expect Oric Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Stock Performance

ORIC opened at $10.04 on Monday. The business's fifty day moving average is $9.94 and its two-hundred day moving average is $8.11. The company has a market cap of $855.86 million, a price-to-earnings ratio of -5.36 and a beta of 1.69. Oric Pharmaceuticals has a one year low of $3.90 and a one year high of $14.67.

Wall Street Analysts Forecast Growth

ORIC has been the subject of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Oppenheimer dropped their target price on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. LADENBURG THALM/SH SH began coverage on Oric Pharmaceuticals in a research note on Tuesday, July 8th. They set a "buy" rating and a $15.00 price target for the company. Wedbush restated an "outperform" rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Finally, HC Wainwright restated a "buy" rating and set a $21.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $18.57.

Insider Activity at Oric Pharmaceuticals

In related news, Director Angie You acquired 26,597 shares of Oric Pharmaceuticals stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of $9.39 per share, with a total value of $249,745.83. Following the purchase, the director directly owned 26,597 shares in the company, valued at $249,745.83. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the sale, the chief financial officer directly owned 68,317 shares of the company's stock, valued at approximately $717,328.50. This represents a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,000 shares of company stock worth $416,289. 5.55% of the stock is owned by insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC boosted its stake in shares of Oric Pharmaceuticals by 56.0% during the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock worth $174,000 after acquiring an additional 11,198 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Oric Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after buying an additional 473,600 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock valued at $1,645,000 after buying an additional 24,778 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after acquiring an additional 3,131 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Oric Pharmaceuticals during the 1st quarter worth about $276,000. 95.05% of the stock is owned by institutional investors.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.